Company Information
CIN
Status
Date of Incorporation
07 January 2010
State / ROC
Delhi / ROC Delhi
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
12,587,500
Authorised Capital
25,000,000
Directors
Arjun Surya
Director/Designated Partner
over 2 years ago
over 2 years ago
Sandeep Gupta
Director/Designated Partner
over 2 years ago
over 2 years ago
Manish Tandon
Director
over 2 years ago
over 2 years ago
Patents
The invention provides a method for preparing sulphoalkyl ether ß cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether ß cyclodextrin. The...
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
A method for determining the genetic polymorphism pattern in the “Stimulator of Interferon Genes” (STING) gene in a subject, the method comprising amplifying, in a sample obtained from a subject, a sequence of genomic DNA comprising a single nucleotide polymorphism (SNP) within the STING gene; and performing restric...
The present invention relates to compounds of formula (I). The compounds may be used to modulate the acetyl coenzyme A synthetase short chain2(ACSS2) protein and may thereby treat, ameliorate or prevent a disease selected from cancer, bacterial infection, viral infection, parasitic infection, fungal infection, neuro...
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, lupus, sepsis, rheumatoid arthritis (RA), type I di...
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, lupus, sepsis, rheumatoid arthritis (RA), type I di...
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, lupus, sepsis, rheumatoid arthritis (RA), type I di...
The present invention relates to compounds of formula (I). The compounds may be used to modulate activity of the HPK-1 protein, and thereby treat cancer, viral infection and immune-mediated disorders.
Registered Trademarks
[Class : 42] Bio Tech R&D For Drug Discovery.
[Class : 42] Bio Tech R&D For Drug Discovery.
[Class : 42] Bio Tech R&D For Drug Discovery.
View +1 more Brands for Curadev Pharma Private Limited.
Charges
24 April 2017
Hdfc Bank Limited
10 Crore
25 March 2011
Icici Bank Limited
6 Crore
09 February 2021
Hdfc Bank Limited
25 Crore
09 February 2021
Hdfc Bank Limited
0
25 March 2011
Icici Bank Limited
0
24 April 2017
Hdfc Bank Limited
0
09 February 2021
Hdfc Bank Limited
0
25 March 2011
Icici Bank Limited
0
24 April 2017
Hdfc Bank Limited
0
09 February 2021
Hdfc Bank Limited
0
25 March 2011
Icici Bank Limited
0
24 April 2017
Hdfc Bank Limited
0
Documents
Form DPT-3-24062020-signed
Form MGT-7-11122019_signed
List of share holders, debenture holders;-09122019
XBRL document in respect Consolidated financial statement-26112019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-26112019
Form AOC-4(XBRL)-26112019_signed
Form DPT-3-26062019
List of share holders, debenture holders;-12112018
Form MGT-7-12112018_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-28102018
XBRL document in respect Consolidated financial statement-28102018
Form AOC-4(XBRL)-28102018_signed
Form CHG-4-12042018_signed
Letter of the charge holder stating that the amount has been satisfied-12042018
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-10112017
XBRL document in respect Consolidated financial statement-10112017
Form AOC-4(XBRL)-10112017_signed
List of share holders, debenture holders;-08112017
Form MGT-7-08112017_signed
Form ADT-3-23102017-signed
Form ADT-1-13102017_signed
Copy of the intimation sent by company-13102017
Copy of written consent given by auditor-13102017
Copy of resolution passed by the company-13102017
Resignation letter-12102017
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-14072017
Form CHG-1-28062017-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20170628
Instrument(s) of creation or modification of charge;-21062017
Optional Attachment-(1)-03122016
